Full text
PDFPage 191
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barrett-Connor E. Hormone replacement and cancer. Br Med Bull. 1992 Apr;48(2):345–355. doi: 10.1093/oxfordjournals.bmb.a072550. [DOI] [PubMed] [Google Scholar]
- Chlebowski R. T., Butler J., Nelson A., Lillington L. Breast cancer chemoprevention. Tamoxifen: current issues and future prospective. Cancer. 1993 Aug 1;72(3 Suppl):1032–1037. doi: 10.1002/1097-0142(19930801)72:3+<1032::aid-cncr2820721315>3.0.co;2-o. [DOI] [PubMed] [Google Scholar]
- Colditz G. A., Stampfer M. J., Willett W. C., Hennekens C. H., Rosner B., Speizer F. E. Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women. JAMA. 1990 Nov 28;264(20):2648–2653. [PubMed] [Google Scholar]
- McDonald C. C., Stewart H. J. Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. BMJ. 1991 Aug 24;303(6800):435–437. doi: 10.1136/bmj.303.6800.435. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Posthuma W. F., Westendorp R. G., Vandenbroucke J. P. Cardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased? BMJ. 1994 May 14;308(6939):1268–1269. doi: 10.1136/bmj.308.6939.1268. [DOI] [PMC free article] [PubMed] [Google Scholar]